Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Puff Puff Post

DECEMBER 2, 2019

The FDA’s Consumer Update reiterated that, with the exception of Epidiolex (a CBD drug for rare forms of epilepsy), the FDA hasn’t approved any other forms of CBD. This is mainly due to a lack of data. billion, and is expected to grow dramatically by 2025.

CBD 52

CBD Food Pets Safety 52

Puff Puff Post

DECEMBER 28, 2018

An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. This is on par with the cost currently seen for those afflicted with ADHD and diabetes, with predictions for the cost to skyrocket further by 2025. CBD Oil For Autism: The Method and Results of Dr. Aran’s Study.

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

OCTOBER 17, 2019

Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma. billion in 2025, according to Grandview Research.

Law 40

Law Seed-To-Sale Hemp Recreational 40